Elizabeth A. Raetz

20.6k total citations · 1 hit paper
245 papers, 7.7k citations indexed

About

Elizabeth A. Raetz is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Hematology. According to data from OpenAlex, Elizabeth A. Raetz has authored 245 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 217 papers in Public Health, Environmental and Occupational Health, 116 papers in Pediatrics, Perinatology and Child Health and 91 papers in Hematology. Recurrent topics in Elizabeth A. Raetz's work include Acute Lymphoblastic Leukemia research (217 papers), Childhood Cancer Survivors' Quality of Life (111 papers) and Acute Myeloid Leukemia Research (52 papers). Elizabeth A. Raetz is often cited by papers focused on Acute Lymphoblastic Leukemia research (217 papers), Childhood Cancer Survivors' Quality of Life (111 papers) and Acute Myeloid Leukemia Research (52 papers). Elizabeth A. Raetz collaborates with scholars based in United States, Canada and Germany. Elizabeth A. Raetz's co-authors include William L. Carroll, Stephen P. Hunger, Meenakshi Devidas, Mignon L. Loh, Naomi Winick, Michael J. Borowitz, David T. Teachey, Wanda L. Salzer, Paul S. Gaynon and Teena Bhatla and has published in prestigious journals such as JAMA, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Elizabeth A. Raetz

237 papers receiving 7.6k citations

Hit Papers

Effect of Postreinduction Therapy Consolidation With Blin... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia
    2021 207 citations Patrick A. Brown, Lingyun Ji et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elizabeth A. Raetz United States 48 5.4k 3.0k 2.9k 2.2k 1.6k 245 7.7k
Paul S. Gaynon United States 60 8.6k 1.6× 5.1k 1.7× 5.1k 1.8× 2.4k 1.1× 2.0k 1.2× 193 11.5k
Anthony V. Moorman United Kingdom 51 6.5k 1.2× 2.4k 0.8× 7.1k 2.5× 1.7k 0.8× 2.6k 1.6× 183 10.2k
Mats Heyman Sweden 39 2.6k 0.5× 1.9k 0.6× 1.3k 0.4× 984 0.5× 1.3k 0.8× 152 4.6k
Anjali S. Advani United States 41 3.0k 0.6× 894 0.3× 3.5k 1.2× 2.9k 1.3× 1.6k 1.0× 298 7.1k
Harland N. Sather United States 64 7.9k 1.5× 5.0k 1.6× 4.7k 1.6× 2.3k 1.1× 2.8k 1.7× 188 13.1k
Elisabeth R. van Wering Netherlands 40 3.1k 0.6× 1.3k 0.4× 2.4k 0.8× 653 0.3× 1.4k 0.8× 101 4.6k
Michael Rytting United States 31 2.1k 0.4× 804 0.3× 2.1k 0.7× 1.3k 0.6× 1.1k 0.7× 96 4.2k
Susana C. Raimondi United States 62 8.1k 1.5× 2.6k 0.9× 9.4k 3.2× 2.5k 1.2× 5.6k 3.5× 259 15.3k
Peter F. Coccia United States 44 1.7k 0.3× 1.1k 0.4× 1.7k 0.6× 1.5k 0.7× 1.3k 0.8× 108 5.7k
Deepa Bhojwani United States 31 2.2k 0.4× 1.2k 0.4× 1.1k 0.4× 957 0.4× 731 0.5× 111 3.5k

Countries citing papers authored by Elizabeth A. Raetz

Since Specialization
Citations

This map shows the geographic impact of Elizabeth A. Raetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth A. Raetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth A. Raetz more than expected).

Fields of papers citing papers by Elizabeth A. Raetz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth A. Raetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth A. Raetz. The network helps show where Elizabeth A. Raetz may publish in the future.

Co-authorship network of co-authors of Elizabeth A. Raetz

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth A. Raetz. A scholar is included among the top collaborators of Elizabeth A. Raetz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth A. Raetz. Elizabeth A. Raetz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elgarten, Caitlin W., John A. Kairalla, Joel Thompson, et al.. (2023). SARS‐CoV‐2 infections in patients enrolled on the Children's Oncology Group standard‐risk B‐cell acute lymphoblastic leukemia trial, AALL1731. SHILAP Revista de lepidopterología. 4(3). 745–750. 2 indexed citations
2.
Evensen, Nikki A., Yan Zhang, Jiyuan Hu, et al.. (2023). Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome. Blood Advances. 7(15). 3928–3931. 1 indexed citations
3.
Hibbitts, Emily, Meenakshi Devidas, Moira K. Whitley, et al.. (2023). Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer. 70(11). e30634–e30634. 2 indexed citations
4.
Szymczak, Julia E., Kelly Getz, Catherine Aftandilian, et al.. (2023). Child and family perceptions of satisfaction with neutropenia management in pediatric acute myeloid leukemia. Pediatric Blood & Cancer. 70(8). e30420–e30420. 2 indexed citations
5.
Hogan, Laura, Patrick A. Brown, Lingyun Ji, et al.. (2023). Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. Journal of Clinical Oncology. 41(25). 4118–4129. 33 indexed citations
6.
Foroutan, Farid, Lehana Thabane, Mignon L. Loh, et al.. (2023). Impact of Vincristine-Steroid Pulses in Maintenance for B-Cell Pediatric ALL: A Systematic Review and Meta-Analysis. Blood. 141(24). 2944–2954. 3 indexed citations
7.
Rheingold, Susan R., Lingyun Ji, Lia Gore, et al.. (2023). Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood. 142(Supplement 1). 2876–2876. 2 indexed citations
8.
Kairalla, John A., Emily Hibbitts, Meenakshi Devidas, et al.. (2022). Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. JNCI Journal of the National Cancer Institute. 114(8). 1167–1175. 12 indexed citations
9.
McNeer, Jennifer L., Maureen M. O’Brien, Susan R. Rheingold, et al.. (2021). A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. Blood. 138(Supplement 1). 3398–3398. 8 indexed citations
10.
11.
12.
13.
Gupta, Sumit, Cindy Wang, Elizabeth A. Raetz, et al.. (2020). Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group. Journal of Clinical Oncology. 38(17). 1897–1905. 124 indexed citations
14.
15.
16.
Wood, Brent L., David Wu, Beryl Crossley, et al.. (2017). Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 131(12). 1350–1359. 130 indexed citations
17.
Larsen, Eric, Meenakshi Devidas, Si Chen, et al.. (2016). Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232. Journal of Clinical Oncology. 34(20). 2380–2388. 231 indexed citations
18.
19.
Carroll, William L. & Elizabeth A. Raetz. (2005). Building better therapy for children with acute lymphoblastic leukemia. Cancer Cell. 7(4). 289–291. 5 indexed citations
20.
Raetz, Elizabeth A., et al.. (2002). The Nucleophosmin-Anaplastic Lymphoma Kinase Fusion Protein Induces c-Myc Expression in Pediatric Anaplastic Large Cell Lymphomas. American Journal Of Pathology. 161(3). 875–883. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul S. Gaynon Breakdown of academic impact, for papers by Anthony V. Moorman Breakdown of academic impact, for papers by Mats Heyman Breakdown of academic impact, for papers by Anjali S. Advani Breakdown of academic impact, for papers by Harland N. Sather Breakdown of academic impact, for papers by Elisabeth R. van Wering Breakdown of academic impact, for papers by Michael Rytting Breakdown of academic impact, for papers by Susana C. Raimondi Breakdown of academic impact, for papers by Peter F. Coccia Breakdown of academic impact, for papers by Deepa Bhojwani
Rankless by CCL
2026